Brassinolide (A3265): Plant Growth Regulator & Apoptosis Inducer

Executive Summary: Brassinolide is a plant-derived steroidal growth regulator with high bioactivity in both plant and mammalian systems. It regulates plant morphogenesis, including leaf and flower formation, via well-characterized brassinosteroid pathways (source: Valdés et al., 2025). In cancer research, Brassinolide induces apoptosis in PC-3 human prostate cancer cells by increasing caspase-3 activity and suppressing Bcl-2 (source: internal review). In diabetic rat models, oral Brassinolide administration lowers blood glucose without detectable toxicity (source: internal review). Brassinolide (A3265, APExBIO) is a benchmark tool for translational research across plant and biomedical fields. Its solubility, storage, and workflow parameters are now standardized and reproducible for laboratory use (source: product_spec).

Biological Rationale

Brassinolide is a naturally occurring brassinosteroid, first identified in Brassica napus L., and is essential for normal plant growth and development. As the most bioactive member of the brassinosteroid family, it promotes cell elongation, vascular differentiation, leaf expansion, and reproductive development (source: Valdés et al., 2025). The biosynthesis of Brassinolide proceeds through well-established pathways involving castasterone as a direct precursor. In research models, Brassinolide is also used for its cross-kingdom activity, including the induction of apoptosis in mammalian cancer cells and metabolic modulation in diabetic models (source: internal review).

Mechanism of Action of Brassinolide

In plants, Brassinolide binds to the BRI1 receptor kinase, triggering a phosphorylation cascade that modulates gene expression involved in cell division, elongation, and morphogenesis (source: Valdés et al., 2025). In mammalian cells, particularly PC-3 prostate cancer cells, Brassinolide induces apoptosis by increasing caspase-3 activity and decreasing anti-apoptotic Bcl-2 protein levels, resulting in cell cycle arrest at the G2/M phase (source: internal review). The compound also elicits characteristic apoptotic morphological changes, such as cell shrinkage and DNA fragmentation. In diabetic rat models, Brassinolide lowers blood glucose, though the precise mechanism likely involves modulation of insulin signaling or glucose transport, with no observed toxicity at effective doses (source: internal review).

Evidence & Benchmarks

• Brassinolide exhibits maximal plant growth regulatory activity in rice lamina inclination tests, outperforming several synthetic analogs at concentrations as low as 1 × 10⁻⁸ M (source: Valdés et al., 2025).
• In PC-3 prostate cancer cells, Brassinolide increases caspase-3 activity and decreases Bcl-2 protein levels, inducing apoptosis with G2/M cell cycle arrest (source: internal review).
• Oral administration of Brassinolide significantly reduces blood glucose in alloxan-induced diabetic rats, with no detectable toxicity observed during the study period (source: internal review).
• Brassinolide is a solid with a molecular weight of 480.68 g/mol, soluble at ≥48.1 mg/mL in DMSO and ≥52.3 mg/mL in ethanol upon gentle warming and ultrasonic treatment, but insoluble in water (source: product_spec).
• Stock solutions in DMSO can be stored at -20°C for several months with no loss of potency (source: product_spec).

This article elucidates and extends the practical findings of "Brassinolide: Dual-Function Growth Regulator and Apoptosis Inducer" by providing granular protocol conditions, and updates the cross-domain efficacy benchmarked in "Brassinolide (A3265): Plant Growth Regulator & Apoptosis ..." by integrating latest in vivo metabolic data.

Applications, Limits & Misconceptions

Brassinolide is primarily used in research contexts: as a plant growth regulator in morphogenesis and development studies, as an apoptosis inducer in prostate cancer and other cancer cell models, and in metabolic research for diabetes models. Its dual-action profile enables comparative studies in plant and mammalian systems. However, its application outside controlled research environments is limited by solubility constraints and the need for precise dosing.

Common Pitfalls or Misconceptions

• Brassinolide is not effective as a cancer treatment in clinical settings; its current use is strictly preclinical and investigational (source: internal review).
• It does not dissolve in water, and improper solvent use leads to unreliable assay results (source: product_spec).
• Long-term storage of Brassinolide solutions at temperatures above -20°C results in degradation and loss of bioactivity (source: product_spec).
• The effects observed in animal models may not directly translate to humans due to metabolic and pharmacokinetic differences (workflow_recommendation).
• Brassinolide is not interchangeable with other brassinosteroids; structure–activity relationships are bioassay-specific (source: Valdés et al., 2025).

Workflow Integration & Parameters

Protocol Parameters

• plant growth bioassay (rice lamina inclination test) | 1 × 10⁻⁸ M | reproducible for RLIT, BSI | establishes benchmark bioactivity and SAR, as per RLIT | DOI
• apoptosis assay in PC-3 cells | 10–50 μM | mammalian cell apoptosis studies | dose range yielding caspase-3 activation and Bcl-2 suppression | workflow_recommendation
• blood glucose assay in diabetic rat model | 1–10 mg/kg oral | in vivo metabolic research | range shown to reduce glucose without toxicity | internal review
• solubility in DMSO | ≥48.1 mg/mL (warmed, ultrasound) | solution preparation | ensures reliable stock solutions | product_spec
• storage temperature | -20°C (solid/solution) | all research areas | preserves compound integrity | product_spec

For detailed assay design and comparative benchmarks, see the Brassinolide (A3265) product page from APExBIO.

Conclusion & Outlook

Brassinolide (A3265) is a rigorously validated dual-function agent for plant growth regulation and apoptosis induction in cancer cell models. Reliable bioactivity benchmarks and clear protocol parameters enable robust experimental design across domains. Emerging data on its metabolic effects in diabetic models position Brassinolide as a catalyst for translational research, though current limitations confine its use to laboratory settings. Further studies will clarify its cross-kingdom mechanisms and optimize workflows for advanced applications (source: Valdés et al., 2025).